Multifaceted roles of APOE in Alzheimer disease

In the paper

“Indeed, some studies have suggested an interaction between APOE genotype and several of these modifiable risk factors, whereby carrying the APOEε4 allele would multiply the increased AD risk associated with the risk factor alone (for example, cardiovascular risk factors30) or counteract the reduced AD risk conferred by a protective factor, such as education attainment31 or physical exercise32.”

What the sources say

• Partly supported

  The Results report interactions between APOE4 and cardiovascular risk factors, including hypertension, in predicting incident cognitive impairment without dementia (CIND). This supports the point attached to citation 30, but the study measured CIND rather than Alzheimer disease risk. Education and exercise are attached to other citations in the citing sentence. (LLM, conf=0.88)

  cites [30] Kolli, A. et al. Interactions between the apolipoprotein E4 gene and modifiable risk factors for cognitive impairment: a nationally representative panel study. BMC Geriatr. 22, 938 (2022). sourceExperimental — accuracy not yet measured
• Disputed

  Split into 2 atoms — 0 confirmed, 0 partially supported, 2 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Checked by a reasoning model — may be wrong.

  cites [31] Langella, S. et al. Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer’s disease. Nat. Commun. 14, 5120 (2023). sourceExperimental — accuracy not yet measured
• Partly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [32] Park, S.-Y. et al. Modifying effects of race and ethnicity and APOE on the association of physical activity with risk of Alzheimer’s disease and related dementias. Alzheimers Dement. 19, 507–517 (2023). sourceExperimental — accuracy not yet measured

In the paper

“However, the effect size of the APOE genotype on AD risk is now known to depend on a number of variables, including demographics such as race and ethnicity, age and sex, and whether the AD diagnosis is made on clinical or neuropathological8 grounds, or confirmed with biomarkers9.”

What the sources say

• Supported

  Citation 8 is attached to the distinction between clinical and neuropathological diagnosis, not to the separate biomarker clause cited to source 9. The Discussion reports a significantly greater effect of APOE genotypes on Alzheimer’s dementia odds ratios in neuropathologically confirmed cases than in unconfirmed cases; the Results give odds ratios for both groups. (LLM, conf=0.94)

  cites [8] Reiman, E. M. et al. Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat. Commun. 11, 667 (2020). source
• Partly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [9] Mattsson, N. et al. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer’s disease. Alzheimers Dement. 14, 913–924 (2018). sourceExperimental — accuracy not yet measured

In the paper

“Large meta-analyses of genome-wide association studies (GWAS) have uncovered more than 80 other risk and protective loci19,20 that could potentially augment or attenuate the APOE-linked AD risk.”

What the sources say

• Partly supported

  The Genome-wide inferences section (page unavailable) reports that this GWAS meta-analysis identified 38 independent Alzheimer’s disease loci, supporting the general point that GWAS have found loci beyond APOE. It does not substantiate the claim of more than 80 other loci or show that those loci augment or attenuate APOE-linked risk. (LLM, conf=0.88)

  cites [19] Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat. Genet. 53, 1276–1282 (2021). sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion reports a large GWAS meta-analysis identifying 75 independent loci associated with Alzheimer’s disease and related dementias, not more than 80. The Methods state that the APOE locus was excluded, and the Discussion describes risk prediction from other variants in addition to APOE status. Thus the source supports the general point about additional loci affecting risk, but not the claimed count. (LLM, conf=0.87)

  cites [20] Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022). sourceExperimental — accuracy not yet measured

In the paper

“This moderating effect has been elegantly shown by comparing the polygenic risk score (PRS) of a cohort of people homozygous for APOEε4 who either had early-onset (<65 years) AD or were still cognitively unimpaired at age >75 (‘resilient’); the resilient cohort had a much lower PRS than the early-onset cohort21.”

What the sources say

• Partly supported

  The Methods (Participants; page not available) describe APOE ε4 homozygotes with early-onset AD and older cognitively healthy controls, and the Abstract (Results; page not available) reports a significantly higher AD polygenic risk score in the cases. The age cutoffs differ slightly: the paper includes cases with onset at 65 (≤65) and controls aged 75 (≥75), whereas the claim specifies <65 and >75. (LLM, conf=0.85)

  cites [21] Huq, A. J. et al. Polygenic score modifies risk for Alzheimer’s disease in APOE ε4 homozygotes at phenotypic extremes. Alzheimers Dement. 13, e12226 (2021). sourceExperimental — accuracy not yet measured

In the paper

“Interestingly, APOE mRNA expression levels seem to be higher in astrocytes from APOEε4 homozygous individuals with European versus African local ancestry14; this observation could be owing to substantial differences in the frequency of certain SNPs that impact the regulation of the APOE gene expression15.”

What the sources say

• Supported

  The Methods describe homozygous APOEε4 patients with European or African local ancestry. The Results report higher APOEε4 expression in European-ancestry samples and identify an astrocyte cluster with high expression specific to that group. The claim’s tentative wording is consistent with those findings. (LLM, conf=0.90)

  cites [14] Griswold, A. J. et al. Increased APOE ε4 expression is associated with the difference in Alzheimer’s disease risk from diverse ancestral backgrounds. Alzheimers Dement. 17, 1179–1188 (2021). source

In the paper

“Although APOEε4 homozygosity may approach 100% penetrance for Aβ deposition in the brain16, even for white or East Asian people, being homozygous for APOEε4 is not synonymous with developing AD dementia”

What the sources say

• Supported

  The Results section on biological penetrance reports that nearly all APOE4 homozygotes had abnormal CSF Aβ levels by age 65, while 75% had positive amyloid scans; biomarker positivity increased with age. It also reports that nearly all had intermediate or high Alzheimer’s neuropathological-change scores. These findings support the hedged claim that penetrance for brain Aβ deposition may approach 100%, though the paper does not report 100% amyloid-scan positivity. (LLM, conf=0.85)

  cites [16] Fortea, J. et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease. Nat. Med. 30, 1284–1291 (2024). source

In the paper

“However, not all epidemiological studies have detected these interactions33.”

What the sources say

• Supported

  The Results section reports no significant interaction between APOE ε4 status and lifestyle profiles on memory decline (P=0.52) in this population-based cohort. This study therefore supports the statement that not all epidemiological studies have detected such interactions. (LLM, conf=0.93)

  cites [33] Jia, J. et al. Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study. Br. Med. J. 380, e072691 (2023). source

In the paper

“By contrast, reported estimates of the population attributable fraction of dementia for these modifiable risk factors, meaning the percentage of dementia cases that could be prevented if each factor was eliminated from the population, are higher in Black and Hispanic people than in white and Asian people, which points to complex genome × environment interactions34,35.”

What the sources say

• Supported

  The Results report higher combined population-attributable fractions for Latino (33.3%) and African American (27.8%) participants than for White (21.9%) and Japanese American (14.2%) participants. The Introduction also reports the same ordering in two earlier US estimates. (LLM, conf=0.94)

  cites [34] Park, S.-Y. et al. Racial and ethnic differences in the population-attributable fractions of Alzheimer disease and related dementias. Neurology 102, e208116 (2024). source
• Supported

  The Discussion states that the proportion of potentially preventable dementia cases was considerably higher among Black and Hispanic individuals than among White and Asian individuals. The Results report combined population attributable fractions of 45.6% and 46.7% for Black and Hispanic individuals, versus 39.4% and 35.8% for White and Asian individuals. The citing authors’ inference about genome × environment interactions is separate from the estimate attributed to this paper. (LLM, conf=0.94)

  cites [35] Lee, M. et al. Variation in population attributable fraction of dementia associated with potentially modifiable risk factors by race and ethnicity in the US. JAMA Netw. Open 5, e2219672 (2022). source

In the paper

“The R136S (Christchurch) mutation has been reported to confer protection against AD on the basis of a unique individual carrying the PSEN1 E280A mutation who was homozygous for the APOEε3 allele with the R136S mutation36.”

What the sources say

• Supported

  The Abstract describes a PSEN1 E280A carrier who remained cognitively unimpaired until her seventies and had two copies of APOE3 Christchurch (R136S). It identifies APOE3ch homozygosity as her most likely genetic modifier, while acknowledging that other factors could have contributed to her resistance. (LLM, conf=0.90)

  cites [36] Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680–1683 (2019). source

In the paper

“In contrast to Aβ pathology, the existence of a direct effect of APOE genotype on the severity of tau neurofibrillary tangle pathology remains controversial, with most studies agreeing that APOEε4-linked effect on tangles is primarily indirect, mediated through its increase of Aβ plaque burden46–48,53.”

What the sources say

• Supported

  In “Amyloid mediates the association of the e4 allele to tangles” (page not provided), the e4–tangle association fell by more than 50% and was no longer significant after adjustment for amyloid load. The Discussion describes this as strong evidence that amyloid mediates the association, while allowing for smaller effects through other mechanisms. This supports the cited paper’s contribution to the sentence’s indirect-effect claim. (LLM, conf=0.88)

  cites [46] Bennett, D. A. et al. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J. Neurol. Neurosurg. Psychiatry 76, 1194–1199 (2005). source
• Partly supported

  The Abstract and Discussion (page numbers not supplied) report evidence that neuritic plaques mediate the association of APOE ε4 with tangles, especially neocortical tangles. The paper does not establish that most studies agree, and its Discussion cautions that its correlational data cannot establish the proposed causal pathway. (LLM, conf=0.84)

  cites [47] Mungas, D., Tractenberg, R., Schneider, J. A., Crane, P. K. & Bennett, D. A. A 2-process model for neuropathology of Alzheimer’s disease. Neurobiol. Aging 35, 301–308 (2014). sourceExperimental — accuracy not yet measured
• Supported

  The Discussion states that the APOEε4–tangle association was largely explained by its effect on plaques and says this agrees with prior work. The Results likewise report no direct effect on tangles, but suggest an indirect pathway mainly through neuritic plaques. These passages support the attributed mechanism, though they do not quantify how many studies agree. (LLM, conf=0.91)

  cites [48] Serrano-Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A. & Hyman, B. T. APOEε2 is associated with milder clinical and pathological Alzheimer disease. Ann. Neurol. 77, 917–929 (2015). source

In the paper

“Of note, although CAA typically affects leptomeningeal and cortical medium- and small-sized arteries, a subtype of capillary CAA has been associated with APOEε4 carriage51,52.”

What the sources say

• Supported

  The Discussion reports this study’s finding that APOE ε4 is associated with the presence of capillary CAA. It also describes capillary involvement as a distinct morphological type of CAA, matching the citing sentence’s reference to a subtype. (LLM, conf=0.94)

  cites [51] Yu, L. et al. APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiol. Aging 36, 2946–2953 (2015). source
• ?Not checked — no full text of the sourcecites [52] Thal, D. R. et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE ε4-associated subtype of sporadic Alzheimer’s disease. Acta Neuropathol. 120, 169–183 (2010). source

In the paper

“This mutation has been associated with a reduction in fibrillar Aβ plaque by amyloid PET and neuropathological examination44.”

What the sources say

• Supported

  The Results report an APOE3-Jac carrier in an amyloid-negative PET cohort of exceptionally aged individuals. In the same section, neuropathological examination found typical cored Aβ plaques in APOE3 brains, whereas APOE3-Jac brains had few diffuse deposits or none. The PET evidence comes from a cohort selected for amyloid negativity, rather than a direct PET comparison between carriers and noncarriers. (LLM, conf=0.86)

  cites [44] Liu, C.-C. et al. APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Sci. Transl. Med. 13, eabc9375 (2021). source

In the paper

“Compared with APOEε3 homozygosis, APOEε4 carriage has been independently associated with increased cerebrovascular burden in the form of gross (macro) infarcts in some studies55, but not others50, whereas APOEε2 is associated with more severe ischaemic small vessel disease in the form of arteriolosclerosis, especially in individuals aged 90 years and older55.”

What the sources say

• Supported

  The Results (APOE and CVD, Macroinfarcts; page not provided) report that ε4 carriers had greater odds of macroinfarcts than ε3/ε3 carriers in the fully adjusted model. This supports the positive association attributed to this paper; the 'but not others' qualification is attached to a different citation. (LLM, conf=0.93)

  cites [55] Lamar, M. et al. APOE genotypes as a risk factor for age-dependent accumulation of cerebrovascular disease in older adults. Alzheimers Dement. 15, 258–266 (2019). source
• Supported

  This source supports the “but not others” portion of the citing sentence, not the positive association assigned to study 55. Its Results (“Other CVD pathologies”) report no significant APOE genotype association with old or recent gross infarcts, and its Discussion (“Non-significant Associations”) specifically says APOE ε4 associations with other cerebrovascular pathologies were non-significant. (LLM, conf=0.93)

  cites [50] Goldberg, T. E., Huey, E. D. & Devanand, D. P. Associations of APOE ε2 genotype with cerebrovascular pathology: a postmortem study of 1275 brains. J. Neurol. Neurosurg. Psychiatry https://doi.org/10.1136/jnnp-2020-323746 (2020). source

In the paper

“Converse to the APOEε4-associated increased likelihood of comorbid proteinopathies in people with AD, the APOEε4 allele also correlates with the presence of AD neuropathological changes in people with a primary neuropathological diagnosis of amyotrophic lateral sclerosis, neocortical Lewy body disease (LBD), primary tauopathies including Pick’s disease, progressive supranuclear palsy (PSP) and”

What the sources say

• Partly supported

  The Results section reports an APOE ε4 association with co-pathology in ALS and neocortical Lewy body disease, and notes that co-pathology cases in corticobasal degeneration, progressive supranuclear palsy and multiple system atrophy included ε4 carriers. It does not establish that ε4 correlates specifically with Alzheimer disease neuropathological changes in every listed diagnosis; Table 3 says all Pick’s disease cases with co-pathologies were ε4-negative. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  cites [65] Robinson, J. L. et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141, 2181–2193 (2018). sourceExperimental — accuracy not yet measured

In the paper

“whereas APOEε2 is associated with more severe ischaemic small vessel disease in the form of arteriolosclerosis, especially in individuals aged 90 years and older55.”

What the sources say

• Supported

  The Discussion reports that APOE ε2 carrier status is associated with greater severity of cerebral small vessel disease in the form of arteriolosclerosis. It also says the association was particularly robust in carriers older than 90 at death; the claim's “90 years and older” is a slight rounding of that threshold. (LLM, conf=0.91)

  cites [55] Lamar, M. et al. APOE genotypes as a risk factor for age-dependent accumulation of cerebrovascular disease in older adults. Alzheimers Dement. 15, 258–266 (2019). source

In the paper

“By contrast, APOEε2 has been found to have both direct and indirect (through Aβ) protective effects against tangle pathology48,49.”

What the sources say

• Supported

  The Results section reports both a direct protective effect of APOEε2 against neurofibrillary tangles and an indirect effect mediated through reduced neuritic plaques. The Discussion describes the indirect pathway as a plaque-lowering effect and links it to Aβ accumulation. (LLM, conf=0.93)

  cites [48] Serrano-Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A. & Hyman, B. T. APOEε2 is associated with milder clinical and pathological Alzheimer disease. Ann. Neurol. 77, 917–929 (2015). source
• Supported

  The Discussion states that APOE ε2 has both a protective indirect influence on Braak stage mediated by amyloid and a direct protective effect. The Results (Mediation) likewise reports direct and indirect effects on tau pathology through amyloid plaque burden. (LLM, conf=0.94)

  cites [49] Goldberg, T. E., Huey, E. D. & Devanand, D. P. Association of APOE ε2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies. Nat. Commun. 11, 4727 (2020). source

In the paper

“One study found that the APOEε2 allele is associated with increased odds of neuropathologically confirmed primary tauopathy (PSP and corticobasal degeneration)66.”

What the sources say

• Partly supported

  The Methods section confirms that the PSP and corticobasal degeneration cases met neuropathologic criteria. The Results section reports increased odds for the APOE ε2/ε2 genotype, not for carrying the ε2 allele generally; the increased odds for corticobasal degeneration in the full sample did not reach statistical significance. (LLM, conf=0.90)

  cites [66] Zhao, N. et al. APOE ε2 is associated with increased tau pathology in primary tauopathy. Nat. Commun. 9, 4388 (2018). sourceExperimental — accuracy not yet measured

In the paper

“Of note, APOEε4 has been associated with greater severity of chronic traumatic encephalopathy68.”

What the sources say

• Partly supported

  The Results report that APOEε4 was associated with higher CTE stage and greater tau burden among donors older than 65. The association with CTE stage was not significant among donors 65 or younger, so the unqualified claim omits an important age restriction. (LLM, conf=0.86)

  cites [68] Atherton, K. et al. Association of APOE genotypes and chronic traumatic encephalopathy. JAMA Neurol. 79, 787–796 (2022). sourceExperimental — accuracy not yet measured

In the paper

“Indeed, several GWAS have linked the rs4420638 and rs10402271 SNPs of the APOE–APOC cluster with higher serum LDL cholesterol levels and an increased risk of coronary artery disease84,85.”

What the sources say

• Supported

  The Results tables on LDL cholesterol and coronary artery disease (pages not provided) list both rs4420638 and rs10402271 in the APOE/C1/C4 cluster. Both are associated with higher LDL cholesterol, and the LDL-increasing alleles are associated with increased coronary artery disease risk. (LLM, conf=0.94)

  cites [84] Willer, C. J. et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40, 161–169 (2008). source
• Partly supported

  The paper reports that the APOE–APOC1–APOC4–APOC2 locus is associated with LDL cholesterol (Abstract; page unavailable). It does not identify rs4420638 or rs10402271 in that finding or link those SNPs to coronary artery disease; its coronary artery disease passage concerns a different locus, 1p13. (LLM, conf=0.88)

  cites [85] Kathiresan, S. et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189–197 (2008). sourceExperimental — accuracy not yet measured

In the paper

“However, another study failed to find such association67 and in a third study the significance of the association was lost when adjusting for AD neuropathological changes49, suggesting a spurious association owing to the strength of the APOEε4–AD link.”

What the sources say

• Supported

  The Results report no significant association between APOE ε2 and risk of CBD or PSP. The Discussion identifies these as tauopathies and describes the study cohorts as pathologically confirmed, matching the claim. (LLM, conf=0.93)

  cites [67] Sabir, M. S. et al. Assessment of APOE in atypical parkinsonism syndromes. Neurobiol. Dis. 127, 142–146 (2019). source

In the paper

“By contrast, no association has been found between the APOE genotype and a primary neuropathological diagnosis of multiple system atrophy67,74.”

What the sources say

• Supported

  The Study Subjects section says the MSA cases were diagnosed using consensus pathologic criteria. The Results section reports no significant association between APOE ε4 or ε2 and MSA risk. Page numbers are unavailable in our copy. (LLM, conf=0.92)

  cites [67] Sabir, M. S. et al. Assessment of APOE in atypical parkinsonism syndromes. Neurobiol. Dis. 127, 142–146 (2019). source
• Supported

  The Results report no difference in APOE genotype between pathologically confirmed MSA patients and controls (P=0.78). This directly supports the claim about a primary neuropathological diagnosis of MSA. (LLM, conf=0.94)

  cites [74] Ogaki, K. et al. Multiple system atrophy and apolipoprotein E. Mov. Disord. 33, 647–650 (2018). source

In the paper

“An association between the APOEε2 allele and higher levels of TDP-43-positive dystrophic neurites (but not neuronal cytoplasmic inclusions) in the motor cortex of individuals with amyotrophic lateral sclerosis and frontotemporal lobar degeneration-TDP has been reported75.”

What the sources say

• Partly supported

  The Results section reports a greater motor-cortex burden of TDP-43-positive dystrophic neurites in APOE2 carriers with ALS or FTLD-MND, but no significant difference in neuronal cytoplasmic inclusions. The claim broadens the studied FTLD-MND group to FTLD-TDP generally; the reported finding does not establish that association across the broader group. (LLM, conf=0.85)

  cites [75] Meneses, A. D. et al. APOE2 exacerbates TDP-43 related toxicity in the absence of Alzheimer pathology. Ann. Neurol. 93, 830–843 (2023). sourceExperimental — accuracy not yet measured

In the paper

“By contrast, APOEε2 has been associated with reduced risk of coronary and carotid artery diseases in diverse populations86.”

What the sources say

• Partly supported

  The Results (Carotid Intima Media Thickness Association; page unavailable) report reduced carotid intima-media thickness with APOE ε2 in European- and African-ancestry cohorts. The Methods and Results passage also reports reduced coronary heart disease risk. Carotid intima-media thickness is a measure of subclinical atherosclerosis, however, not a measured reduction in the risk of clinical carotid artery disease. (LLM, conf=0.88)

  cites [86] Natarajan, P. et al. Multiethnic exome-wide association study of subclinical atherosclerosis. Circ. Cardiovasc. Genet. 9, 511–520 (2016). sourceExperimental — accuracy not yet measured

In the paper

“and in a third study the significance of the association was lost when adjusting for AD neuropathological changes49, suggesting a spurious association owing to the strength of the APOEε4–AD link.”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [49] Goldberg, T. E., Huey, E. D. & Devanand, D. P. Association of APOE ε2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies. Nat. Commun. 11, 4727 (2020). source

In the paper

“Furthermore, the ε4 allele has been associated with increased risk of a dementia presentation in people with pure α-synucleinopathies70.”

What the sources say

• Supported

  The Abstract Conclusions state that APOE ε4 is a strong risk factor across the Lewy body disease spectrum and suggest that it increases the likelihood of presenting with dementia in a pure synucleinopathy. The Results also report elevated ε4 frequencies in the pure dementia with Lewy bodies and Parkinson disease dementia groups. (LLM, conf=0.94)

  cites [70] Tsuang, D. et al. APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 70, 223–228 (2013). source

In the paper

“APOEε4 has been associated with a faster rate of cognitive decline in people with Parkinson disease, independent of AD neuropathology assessed by levels of CSF biomarkers Aβ42 and pTau69.”

What the sources say

• Supported

  The Results section, “APOE4 accelerates cognitive decline in human patients with PD,” reports faster MoCA decline associated with APOE ε4 after adjustment for CSF Aβ42 and pTau. The authors explicitly state that the association remained significant independently of those biomarkers. The Discussion distinguishes this biomarker-based finding from direct neuropathology assessment, which the study could not perform. (LLM, conf=0.93)

  cites [69] Davis, A. A. et al. APOE genotype regulates pathology and disease progression in synucleinopathy. Sci. Transl. Med. 12, eaay3069 (2020). source

In the paper

“The well-established association between APOE genotype and cognition — whereby APOEε4 accelerates age-related cognitive decline76 and APOEε2 delays it77 — is largely mediated by genotype-specific effects on AD neuropathological changes and, to a lesser extent, on comorbid pathologies46–48,78,79.”

What the sources say

• Partly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [76] Caselli, R. J. et al. Longitudinal modeling of age-related memory decline and the APOE ε4 effect. N. Engl. J. Med. 361, 255–263 (2009). sourceExperimental — accuracy not yet measured
• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [77] Shinohara, M. et al. APOE2 eases cognitive decline during aging: clinical and preclinical evaluations. Ann. Neurol. 79, 758–774 (2016). source
• Partly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [46] Bennett, D. A. et al. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J. Neurol. Neurosurg. Psychiatry 76, 1194–1199 (2005). sourceExperimental — accuracy not yet measured

In the paper

“Cryo-electron microscopy of APOE lipoprotein particles secreted from astrocytes in culture has revealed that APOE forms an anti-parallel dimer that wraps a discoidal lipoparticle in a ‘double-belt’ configuration101.”

What the sources say

• Partly supported

  The Results (Figure 1B; page not given) report that astrocyte-secreted ApoE forms antiparallel dimers on discoidal particles, supporting the double-belt description. But those particles were examined by negative-stain TEM; the cryo-EM analysis in the section “Cryo-EM of recombinant ApoE lipoproteins” used recombinant particles, not particles secreted by cultured astrocytes. (LLM, conf=0.90)

  cites [101] Strickland, M. R. et al. Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins. Neuron 112, 1100–1109.e5 (2024). sourceExperimental — accuracy not yet measured

In the paper

“Indeed, APOE affects the seeding and aggregation of Aβ in an isoform-dependent manner112, and the increased propensity of Aβ to oligomerize in the presence of APOE4 is considered a major mechanism by which APOE4 increases AD risk113–116 (Fig. 2c).”

What the sources say

• Supported

  The Discussion reports a critical role for apoE4 in the early seeding stage of plaque formation and describes stronger enhancement of Aβ fibrillogenesis by apoE4 than apoE3. Together, these passages support an isoform-dependent effect on seeding and aggregation. (LLM, conf=0.90)

  cites [112] Liu, C.-C. et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron 96, 1024–1032.e3 (2017). source

In the paper

“The link between APOE4 and Aβ has been studied extensively for the past three decades, and the interaction between the two proteins has now been established as one of the mechanisms by which the APOEε4 allele increases AD risk109.”

What the sources say

• Partly supported

  The Introduction (page unavailable) says compelling studies show that APOE4 affects Aβ production, clearance and aggregation, supporting an Aβ-related contribution to Alzheimer disease risk. But it also says the exact mechanisms remain unresolved; the Mechanisms of APOE-related neurodegeneration section describes specific protein interactions as suggested rather than established. The claim overstates that certainty. (LLM, conf=0.84)

  cites [109] Tzioras, M., Davies, C., Newman, A., Jackson, R. & Spires-Jones, T. Invited review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 45, 327–346 (2019). sourceExperimental — accuracy not yet measured

In the paper

“and the increased propensity of Aβ to oligomerize in the presence of APOE4 is considered a major mechanism by which APOE4 increases AD risk113–116 (Fig. 2c).”

What the sources say

• Partly supported

  The Discussion reports that apoE4 promotes and stabilizes Aβ oligomerization, but says it is *plausible* that this helps explain the major AD risk associated with APOEε4. The claim overstates that tentative link by calling oligomerization a major mechanism of increased risk. (LLM, conf=0.85)

  cites [113] Hashimoto, T. et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J. Neurosci. 32, 15181–15192 (2012). sourceExperimental — accuracy not yet measured
• ?Could not verify

  Our indexed copy is an Additions and Corrections notice (p. 7267), not the original study's results. Its correction to the Fig. 6 legend describes incubating Aβ with apoE isoforms, but does not say whether APOE4 increases Aβ oligomerization or whether that is a major mechanism of Alzheimer disease risk. Searches for both points found no further relevant passage. (LLM, conf=0.74)

  cites [114] Hori, Y., Hashimoto, T., Nomoto, H., Hyman, B. T. & Iwatsubo, T. Role of apolipoprotein E in β-amyloidogenesis: isoform-specific effects on protofibril to fibril conversion of Aβ in vitro and brain Aβ deposition in vivo. J. Biol. Chem. 293, 7267 (2018). sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion (page unavailable) proposes that apoE4’s detrimental effects are mediated by stabilization of toxic Aβ intermediates. It does not show that apoE4 increases Aβ’s propensity to oligomerize; it reports delayed aggregation and presents the disease mechanism as a hypothesis rather than an established major mechanism. (LLM, conf=0.86)

  cites [115] Garai, K., Verghese, P. B., Baban, B., Holtzman, D. M. & Frieden, C. The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry 53, 6323–6331 (2014). sourceExperimental — accuracy not yet measured

In the paper

“Importantly, Apoe knockout/PS19 mice were relatively spared from any neuronal and hippocampal volume loss when compared with any of the APOE-expressing mice, despite similar levels of tau accumulation compared with APOE3/PS19 mice127.”

What the sources say

• Supported

  The paper’s main text (labelled Abstract in our copy; no page given) says that ApoE knockout P301S mice largely avoided the neuronal loss and brain atrophy seen in mice expressing human ApoE, including atrophy in the hippocampus. It reports significantly higher tau levels in the ApoE4 group than in the other genotypes, consistent with the claim’s comparison of knockout and ApoE3 mice. (LLM, conf=0.87)

  cites [127] Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523–527 (2017). source

In the paper

“Specifically, in a tauopathy mouse model (PS19, overexpressing the MAPT P301S mutation) crossed with APOE-targeted replacement mice (Box 3), APOE had a marked isoform-dependent effect on tau pathology in the absence of Aβ plaques, with APOE4/PS19 mice showing the greatest extent of tau neurofibrillary tangle pathology and neuronal loss and APOE2/PS19 mice the lowest127 (Fig. 2f).”

What the sources say

• Partly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [127] Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523–527 (2017). sourceExperimental — accuracy not yet measured

In the paper

“However, antisense oligonucleotide therapy in mice suggests that lowering APOE levels is less effective after plaque deposition than before plaque deposition124, which reinforces the idea that Aβ plaque deposition is a multistep process.”

What the sources say

• Supported

  The Discussion states that lowering apoE before amyloid deposition had a much larger effect on Aβ accumulation than lowering it after aggregation began. The Results also report reduced plaque pathology with treatment starting at birth, while later treatment did not significantly lower total Aβ deposition. The comparison concerns plaque burden; the paper also reports benefits for neuritic dystrophy with later treatment. (LLM, conf=0.94)

  cites [124] Huynh, T.-P. V. et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of β-amyloidosis. Neuron 96, 1013–1023.e4 (2017). source

In the paper

“and further mouse studies have shown that APOE4 alters the proteolytic processing of αSyn.”

What the sources say

• Supported

  The Introduction identifies C-terminal truncation as proteolytic processing of α-synuclein and describes the study’s APOE3- and APOE4-expressing mouse models. The Results section reports genotype-dependent differences in C-terminally truncated α-synuclein pathology, including greater αSynΔC-122 staining in the midbrain and hypothalamus of APOE4 mice than APOE3 mice. This supports the claim about altered processing, without establishing the mechanism. (LLM, conf=0.88)

  cites [133] Lloyd, G. M. et al. Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis. Acta Neuropathol. Commun. 11, 119 (2023). source

In the paper

“however, APOE itself has also been shown to form aggregates, particularly in its non-lipidated state99,134,135 (Fig. 2).”

What the sources say

• Supported

  The “ApoE and Aβ Fibrilization” section states that non-lipidated ApoE self-associates into dimers, tetramers, and sometimes higher-order oligomers. It also reports ApoE self-aggregation and fibril formation in vitro. Page numbers were not supplied in our copy. (LLM, conf=0.92)

  cites [99] Chen, Y., Strickland, M. R., Soranno, A. & Holtzman, D. M. Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis. Neuron 109, 205–221 (2021). source
• Supported

  The Background reports that lipid-free ApoE4 is aggregation-prone and that ApoE4 aggregates have been observed. The Discussion identifies lipid-free ApoE aggregation as a proposed mechanism of plaque formation, supporting the claim about aggregation in the non-lipidated state. (LLM, conf=0.92)

  cites [134] Nemergut, M. et al. Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer’s disease drug candidate. Mol. Neurodegener. 18, 38 (2023). source
• ?Not checked — no full text of the sourcecites [135] Zhang, Y. et al. A monomeric, biologically active, full-length human apolipoprotein E. Biochemistry 46, 10722–10732 (2007). source

In the paper

“Biochemical studies indicate that APOE4 increases the seeding potential of αSyn131,132, and further mouse studies have shown that APOE4 alters the proteolytic processing of αSyn.”

What the sources say

• Supported

  The Results section (“APOE4 exacerbates α-SYN seeding activity”; page unavailable) reports significantly greater α-synuclein seeding-assay fluorescence in AD brains with Lewy body pathology from APOE4 carriers than from non-carriers. The Discussion explicitly concludes that APOE4 exacerbates α-synuclein seeding ability. (LLM, conf=0.92)

  cites [131] Jin, Y. et al. APOE4 exacerbates α-synuclein seeding activity and contributes to neurotoxicity in Alzheimer’s disease with Lewy body pathology. Acta Neuropathol. 143, 641–662 (2022). source
• Partly supported

  The Results report that low concentrations of apoE4 stimulated α-synuclein aggregation more than the other isoforms. The Discussion treats a seeding mechanism as a possibility, not a demonstrated effect, and notes evidence that complicates it. The study therefore supports increased aggregation under its in vitro conditions, but not a measured increase in seeding potential. (LLM, conf=0.86)

  cites [132] Emamzadeh, F. N., Aojula, H., McHugh, P. C. & Allsop, D. Effects of different isoforms of apoE on aggregation of the α-synuclein protein implicated in Parkinson’s disease. Neurosci. Lett. 618, 146–151 (2016). sourceExperimental — accuracy not yet measured

In the paper

“Indeed, mounting evidence shows that APOE downstream effects converge on the microglial response to protein aggregates, as further discussed subsequently129,130.”

What the sources say

• Supported

  The “APOE and microglia” section (page unavailable) describes APOE-dependent changes in microglial responses to amyloid plaques and tau pathology. It also identifies microglial responses to proteopathic aggregates as relevant to neurodegeneration, supporting the broad paraphrase without implying that all reported effects have the same direction. (LLM, conf=0.88)

  cites [129] Parhizkar, S. & Holtzman, D. M. APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease. Semin. Immunol. 59, 101594 (2022). source
• Partly supported

  The Discussion reports that apoE’s effects on tau pathology and neurodegeneration in a tauopathy mouse model were mediated predominantly through microglial function. The Introduction identifies tau as an aggregated protein, but the paper’s finding does not establish convergence of APOE effects on microglial responses to protein aggregates generally. (LLM, conf=0.83)

  cites [130] Shi, Y. et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med. 216, 2546–2561 (2019). sourceExperimental — accuracy not yet measured

In the paper

“its expression is markedly upregulated by reactive microglia in the brains of individuals with AD96,150.”

What the sources say

• ?Not checked — no full text of the sourcecites [96] Xu, Q. et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26, 4985–4994 (2006). source
• Supported

  The Results section on the AD cortex reports increased APOE expression in microglia near Aβ plaques and identifies the phenotype in human AD. The Methods section also describes APOE measurements in microglia from AD subjects and controls. Page numbers are unavailable in our copy. (LLM, conf=0.91)

  cites [150] Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581.e9 (2017). source

In the paper

“In vitro studies have shown that fragments of APOE, which are more abundant with APOE4 than with APOE3, can cause neuronal mitochondrial dysfunction165,166.”

What the sources say

• Supported

  The background passage labeled Abstract states that apoE4 is more susceptible to cleavage than apoE3 and that apoE3 undergoes cleavage to a lesser extent. The Results report impaired mitochondrial function in Neuro-2a cells expressing apoE4 fragments, supporting the in vitro neuronal-cell finding. Page numbers were not provided for these passages. (LLM, conf=0.90)

  cites [165] Chang, S. et al. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl Acad. Sci. USA 102, 18694–18699 (2005). source
• Partly supported

  The Discussion (page unavailable) reports that an apoE4 fragment perturbs mitochondrial respiratory-complex activity in N2A cells, supporting the in vitro dysfunction claim. It does not say that APOE fragments are more abundant with APOE4 than with APOE3. The paper’s own experiments examine full-length apoE4 rather than establishing that fragment-abundance comparison. (LLM, conf=0.86)

  cites [166] Chen, H.-K. et al. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J. Biol. Chem. 286, 5215–5221 (2011). sourceExperimental — accuracy not yet measured

In the paper

“microglia-specific Apoe knockout Aβ plaque-depositing mice (Box 3) exhibit largely unchanged microglial and Aβ phenotypes except for slightly larger plaques157.”

What the sources say

• Supported

  The Results section on plaque volume reports unchanged plaque counts and overall Aβ levels, with modestly larger dense-core plaques in the hippocampus of 12-month-old knockout mice. The Results section on microglial number and plaque association reports no differences in either measure between 5xFAD and knockout mice. (LLM, conf=0.93)

  cites [157] Henningfield, C. M., Arreola, M. A., Soni, N., Spangenberg, E. E. & Green, K. N. Microglia-specific ApoE knock-out does not alter Alzheimer’s disease plaque pathogenesis or gene expression. Glia 70, 287–302 (2022). source

In the paper

“Apoe knockout mice and LDL receptor (Ldlr)-overexpressing mice — which display low levels of APOE owing to internalization and clearance of APOE lipoproteins — have larger pools of oligodendrocyte progenitor cells and increased myelin coverage of axons, supporting the idea that APOE regulates oligodendrocyte number and function106.”

What the sources say

• Supported

  The Results section reports larger oligodendrocyte progenitor cell pools and greater myelin coverage in Apoe-deficient and LDLR-overexpressing mice. The Introduction explains that LDLR overexpression reduces brain apoE through uptake and degradation of apoE lipoproteins. The paper presents these findings as suggesting regulation of myelination by apoE/LDLR; it does not claim to have directly measured mature oligodendrocyte function. Page numbers were not available in our copy. (LLM, conf=0.92)

  cites [106] Shi, Y. et al. Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron 109, 2413–2426.e7 (2021). source

In the paper

“only astrocytic APOE4 deletion, but not APOE3 deletion, significantly ameliorated tau neurofibrillary tangle burden in tauopathy mice149.”

What the sources say

• Partly supported

  The Results section ('Reducing astrocyte-derived apoE4 decreases phosphorylated tau accumulation'; page unavailable) reports reduced hippocampal AT8 staining after astrocytic APOE4 deletion in female mice, but not male mice or APOE3-deletion mice. It measured phosphorylated-tau deposition rather than neurofibrillary tangle burden directly, and it also found reduced insoluble phosphorylated tau in female APOE3-deletion mice. The claim therefore overgeneralizes both the outcome and the APOE3 comparison. (LLM, conf=0.86)

  cites [149] Wang, C. et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron https://doi.org/10.1016/j.neuron.2021.03.024 (2021). sourceExperimental — accuracy not yet measured

In the paper

“removing APOE4 from neurons in a tauopathy mouse model leads to a significant reduction in tau neurofibrillary tangle pathology and tau-induced neurodegeneration161.”

What the sources say

• Supported

  The Results section, “Removal of APOE4 from neurons drastically reduces tau pathology” (page unavailable), reports a significant decrease in neurofibrillary tangle-bearing cells after neuronal APOE4 removal in PS19 tauopathy mice. The Results section, “Neurodegeneration is reduced after removal of neuronal APOE4” (page unavailable), concludes that the removal protects against tau-mediated neurodegeneration and mitigates neuronal loss. (LLM, conf=0.94)

  cites [161] Koutsodendris, N. et al. Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. Nat. Aging 3, 275–296 (2023). source

In the paper

“the characterization of microglia in astrocyte-specific Apoe knockout mice certainly indicates that microglia are affected by astrocytic APOE148,149.”

What the sources say

• Supported

  The Results section, “Microglial activation after the loss of astrocytic apoE,” reports reduced upregulation of several microglial activation-associated genes in mice lacking astrocytic apoE compared with controls. The Discussion also reports lower plaque-associated microglial activation in those mice and says the findings support a role for astrocytic apoE in astrocyte–microglia signaling. (LLM, conf=0.92)

  cites [148] Mahan, T. E. et al. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis. Mol. Neurodegener. 17, 13 (2022). source
• Supported

  The Results section, “Genetic deletion of astrocytic APOE4 decreases DAM/MGnD genes,” reports changes in microglial gene expression after astrocytic APOE4 removal. The Discussion also states that selective removal of astrocytic apoE4 reduces microglial-mediated phagocytosis. These findings support the claim that microglia are affected by astrocytic APOE. (LLM, conf=0.94)

  cites [149] Wang, C. et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron https://doi.org/10.1016/j.neuron.2021.03.024 (2021). source

In the paper

“Along this line, an antibody against non-lipidated APOE, which is the version most likely to oligomerize, has shown promise in multiple AD mouse models136–139.”

What the sources say

• Partly supported

  The Abstract (page unavailable) reports that lipid-free apoE forms monomers, dimers, and tetramers, supporting the oligomerization part of the sentence. The paper studies apoE binding to phospholipid vesicles; it does not report an antibody treatment or results in Alzheimer disease mouse models. (LLM, conf=0.88)

  cites [136] Garai, K., Baban, B. & Frieden, C. Dissociation of apoE oligomers to monomers is required for high affinity binding to phospholipid vesicles. Biochemistry 50, 2550–2558 (2011). sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction identifies HAE-4 as an antibody that recognizes poorly lipidated human APOE, and the Results report reduced amyloid pathology and improved vascular function in treated mice. The paper does not say that non-lipidated APOE is the form most likely to oligomerize. Its treatment findings concern a particular mouse model; the sentence’s reference to multiple models is not established by this study alone. (LLM, conf=0.84)

  cites [137] Xiong, M. et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci. Transl. Med. 13, eabd7522 (2021). sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction (page unavailable) identifies HAE-4 as an antibody targeting non-lipidated ApoE and describes beneficial effects in amyloid mice; the Results report reduced Aβ plaques and tau pathology in 5XE4 mice. Our copy does not say that non-lipidated ApoE is the form most likely to oligomerize, and this paper tests only one mouse model, although it describes earlier mouse studies. (LLM, conf=0.86)

  cites [138] Gratuze, M. et al. APOE antibody inhibits Aβ‐associated tau seeding and spreading in a mouse model. Ann. Neurol. 91, 847–852 (2022). sourceExperimental — accuracy not yet measured

In the paper

“The characterization of hIPSC-derived neurons indicates that neuronal APOE4 is associated with altered synaptic function, fatty acid accumulation and hyperexcitability143.”

What the sources say

• Partly supported

  The Results section, “Increased synapses, early endosomes and Aβ42 secretion in APOE4 neurons” (page unavailable), reports increased synapse number and excitatory postsynaptic current frequency in iPSC-derived APOE4 neurons, supporting altered synaptic function and increased synaptic activity. It does not establish neuronal hyperexcitability as such. The paper reports cholesterol accumulation in APOE4 astrocytes, not fatty acid accumulation in neurons. (LLM, conf=0.88)

  cites [143] Lin, Y.-T. et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1141–1154.e7 (2018). sourceExperimental — accuracy not yet measured

In the paper

“studies performed in post-mortem brain tissue and in vivo using APOE knock-in mouse models have all associated APOE4 with impaired myelination of oligodendrocytes resulting from altered cholesterol transport163,164.”

What the sources say

• Supported

  The Discussion reports that cholesterol dysregulation in oligodendrocytes leads to impaired myelination and describes a causal link in APOE4 carriers. The Introduction also reports reduced myelination in APOE4 knock-in mice and altered cholesterol homeostasis alongside reduced myelin-associated gene expression in post-mortem human oligodendrocytes. (LLM, conf=0.94)

  cites [163] Blanchard, J. W. et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature 611, 769–779 (2022). source
• Supported

  The Discussion (page not provided) says this study found that APOE4 interferes with oligodendrocyte differentiation by disrupting lipid uptake in a humanized APOE4 mouse model. The Abstract also reports that APOE4 prevented lipid supplementation from restoring myelination during cholesterol depletion. The paper refers to post-mortem human tissue findings from an earlier study; its own experiments include the mouse model and cell cultures. (LLM, conf=0.90)

  cites [164] Mok, K. K.-S. et al. Apolipoprotein E ε4 disrupts oligodendrocyte differentiation by interfering with astrocyte-derived lipid transport. J. Neurochem. 165, 55–75 (2023). source

In the paper

“This upregulation is a key element of a conserved transcriptional signature of reactive microglia that has been found in multiple neurodegenerative diseases150,151.”

What the sources say

• Supported

  The Results section (“Reciprocal induction of APOE and suppression of TGFβ signaling”) identifies Apoe upregulation as part of a common disease-associated microglial signature in mouse models of ALS, AD, and MS. It describes Apoe as one of the most upregulated genes in that signature. (LLM, conf=0.90)

  cites [150] Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581.e9 (2017). source
• Supported

  The Results report a disease-associated microglial transcriptional profile in an Alzheimer’s mouse model and a highly similar profile in an ALS mouse model, including upregulation of Trem2, Tyrobp, Lpl, and Cst7. The Discussion describes DAM as a general program seen across these conditions. The excerpt does not identify which specific upregulation “This” refers to, so the paper confirms the shared-signature point but cannot establish an unnamed gene’s role in it. (LLM, conf=0.86)

  cites [151] Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290.e17 (2017). source

In the paper

“This so-called disease-associated microglial (DAM) response is differentially regulated by the various APOE isoforms, probably through their differential binding to specific surface microglial receptors such as TREM2 (refs. 152,153)”

What the sources say

• Partly supported

  The Results (Testing of microglia-APOE cluster in APOE knock-in mice; page not provided) report APOE-dependent differences in microglial gene expression and suggest regulation through the TREM2–TYROBP axis. The Discussion also links APOE and TREM2 to the switch toward AD-associated microglia. Neither passage establishes that differential binding of APOE isoforms to TREM2 or other surface receptors explains the effect. (LLM, conf=0.88)

  cites [152] Serrano-Pozo, A. et al. Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease. Nat. Aging 1, 919–931 (2021). sourceExperimental — accuracy not yet measured
• Partly supported

  The Results and Discussion (page unavailable) show that APOE ε4, compared with ε3, augments plaque-associated microglial gene expression, including TREM2; the Results also find the DAM signature enriched in plaques. The paper does not establish that differential binding of APOE isoforms to TREM2 or other microglial receptors explains this effect. (LLM, conf=0.87)

  cites [153] Das, S. et al. Distinct transcriptomic responses to Aβ plaques, neurofibrillary tangles, and APOE in Alzheimer’s disease. Alzheimers Dement. 20, 74–90 (2023). sourceExperimental — accuracy not yet measured

In the paper

“removal of both astrocytic APOE3 and APOE4 is protective against Aβ deposition in plaque-depositing mice; specifically, plaque burden was lowered to the levels of Apoe knockout mice148.”

What the sources say

• Partly supported

  The Results (Aβ plaque accumulation in mice lacking astrocytic APOE; page unavailable) report reduced fibrillar plaque burden after astrocytic apoE3 or apoE4 removal, with total fibrillar amyloid burden qualitatively similar to that in Apoe-knockout mice. But the same section reports no significant reduction in male APOE3 mice and a qualitatively higher overall Aβ plaque load in knockout mice. Thus, the claim overgeneralizes the reduction and the comparison with knockout levels. (LLM, conf=0.88)

  cites [148] Mahan, T. E. et al. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis. Mol. Neurodegener. 17, 13 (2022). sourceExperimental — accuracy not yet measured

In the paper

“Post-mortem analysis of brain tissue has shown an association between the APOEε4 allele and a reduced number of oligodendrocytes in the frontal cortex after controlling for the severity of AD neuropathology162.”

What the sources say

• Supported

  The results section, “Intracortical OLs Are Highly Vulnerable to APOE4 Status but Not Braak Stage” (page unavailable), reports significantly lower oligodendrocyte density in the frontal cortex of APOE4 carriers, with little change across Braak stages. The Discussion (page unavailable) likewise describes the postmortem association as more closely related to APOE4 status than to plaque and tangle pathology. (LLM, conf=0.92)

  cites [162] Cheng, G. W.-Y. et al. Apolipoprotein E ε4 mediates myelin breakdown by targeting oligodendrocytes in sporadic Alzheimer disease. J. Neuropathol. Exp. Neurol. 81, 717–730 (2022). source

In the paper

“Together with triggering receptor expressed on myeloid cells 2 (TREM2), APOE has also been shown to regulate microglial response to Aβ plaques and neurofibrillary tangles in AD as well as in other neurodegenerative diseases150.”

What the sources say

• Partly supported

  The Results section reports that microglia in AD patients with TREM2 variants did not cluster around Aβ plaques as they did in patients with common TREM2 variants. The Introduction and Results also describe TREM2-induced APOE signaling as regulating a disease-associated microglial phenotype, including in AD and other neurodegenerative disease models. The passages do not establish a microglial response to neurofibrillary tangles. (LLM, conf=0.87)

  cites [150] Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581.e9 (2017). sourceExperimental — accuracy not yet measured

In the paper

“removing APOE4 specifically from microglia of APOE4/PS19 tauopathy mice rescued a neuroprotective microglial signature157,158.”

What the sources say

• Partly supported

  The Discussion (page unavailable) confirms that the authors knocked out Apoe specifically in microglia, but they studied 5xFAD mice, not APOE4/PS19 tauopathy mice. They report few gene-expression changes and no change in disease-associated microglial genes in their model; they explicitly say the role of microglial Apoe knockout in tauopathy models remains to be determined. The claimed rescue of a neuroprotective microglial signature is therefore not supported by this paper. (LLM, conf=0.86)

  cites [157] Henningfield, C. M., Arreola, M. A., Soni, N., Spangenberg, E. E. & Green, K. N. Microglia-specific ApoE knock-out does not alter Alzheimer’s disease plaque pathogenesis or gene expression. Glia 70, 287–302 (2022). sourceExperimental — accuracy not yet measured
• Partly supported

  The section “Deletion of microglial APOE4 restores protective MGnD” (p. 4) reports that deleting APOE4 in microglia restored the protective MGnD signature in P301S tauopathy mice. Our copy calls the mice P301S, not PS19, so it does not establish the claim’s more specific model designation. (LLM, conf=0.78)

  cites [158] Yin, Z. et al. APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints. Nat. Immunol. 24, 1839–1853 (2023). sourceExperimental — accuracy not yet measured

In the paper

“This process is likely to explain why both Apoe knockout and Trem2 knockout plaque-depositing mice exhibit reduced microglial reactivity against Aβ plaques and their plaques are less compact117,119,122,155.”

What the sources say

• ?Not checked — no full text of the sourcecites [117] Fagan, A. M. et al. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 9, 305–318 (2002). source
• ?Not checked — no full text of the sourcecites [119] Irizarry, M. C. et al. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol. 100, 451–458 (2000). source
• Partly supported

  The Results report reduced glial reactivity and fewer dense-core plaques in APP/PSEN1 mice lacking APOE. The Discussion proposes that inhibition of the APOE–TREM2 pathway could explain the reduced glial reactivity, but does not establish that this pathway causes the change in plaque compaction. The cited paper also does not report the claimed plaque and microglial findings for Trem2-knockout mice. (LLM, conf=0.86)

  cites [122] Hudry, E. et al. Opposing roles of apolipoprotein E in aging and neurodegeneration. Life Sci. Alliance 2, e201900325 (2019). sourceExperimental — accuracy not yet measured
• Partly supported

  The Results and Discussion sections on plaque-associated microglial proliferation and plaque structure (page numbers unavailable) report reduced microglial clustering and less compact plaques in Trem2-knockout 5XFAD mice. The paper does not establish the corresponding findings in Apoe-knockout mice or show that APOE binding to TREM2 explains either knockout phenotype. (LLM, conf=0.87)

  cites [155] Wang, Y. et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213, 667–675 (2016). sourceExperimental — accuracy not yet measured

In the paper

“this microglia-derived APOE has distinct post-translational modifications when compared with APOE produced by astrocytes and this, too, is isoform-dependent156.”

What the sources say

• Partly supported

  The Results section (‘ApoE species differ between astrocytes and microglia’; page unavailable) reports different patterns of glycosylated apoE in the two cell types. It also finds an APOE-genotype difference in intracellular microglial apoE, but no genotype difference in the distribution of secreted astrocytic apoE. Thus, isoform dependence is supported for a specific intracellular form, not for the cell-type difference generally. (LLM, conf=0.85)

  cites [156] Lanfranco, M. F., Sepulveda, J., Kopetsky, G. & Rebeck, G. W. Expression and secretion of apoE isoforms in astrocytes and microglia during inflammation. Glia 69, 1478–1493 (2021). sourceExperimental — accuracy not yet measured

In the paper

“APOE4 astrocytes and microglia have increased glycolytic activity when compared with the same cells expressing APOE3 (refs. 175,176).”

What the sources say

• Partly supported

  The Results section (page unavailable) reports higher glucose flux into late glycolysis—pyruvate and lactate—in E4 astrocytes than in E3 astrocytes. It does not study microglia, and its Discussion reports reduced glucose uptake and potentially reduced flux through early glycolysis in E4 astrocytes, so it does not support a general increase in glycolytic activity in both cell types. (LLM, conf=0.88)

  cites [175] Williams, H. C. et al. APOE alters glucose flux through central carbon pathways in astrocytes. Neurobiol. Dis. 136, 104742 (2020). sourceExperimental — accuracy not yet measured
• Partly supported

  The Results section (‘E4 microglia have increased aerobic glycolysis and higher HIF1α expression’) reports higher basal and compensatory glycolysis in E4 than E3 microglia. But the Results section (‘APOE4 drives immunometabolic changes across the glial transcriptome’) describes E4-associated increases in oxidative phosphorylation and branched-chain amino acid metabolism in astrocytes, not increased astrocyte glycolysis. Page numbers were not provided. (LLM, conf=0.90)

  cites [176] Lee, S. et al. APOE modulates microglial immunometabolism in response to age, amyloid pathology, and inflammatory challenge. Cell Rep. 42, 112196 (2023). sourceExperimental — accuracy not yet measured

In the paper

“Work both in vitro and in vivo has highlighted an APOE isoform-specific impact on lipid droplet accumulation in astrocytes146, neurons177 and microglia178.”

What the sources say

• Supported

  This source is cited for the astrocyte portion of the sentence; separate citations follow neurons and microglia. The Introduction reports increased lipid droplet formation in E4 astrocytes, and the Discussion describes apoE isoform-specific differences in astrocyte lipid droplet formation. This verdict does not assess the separately cited cell types. (LLM, conf=0.91)

  cites [146] Farmer, B. C., Kluemper, J. & Johnson, L. A. Apolipoprotein E4 alters astrocyte fatty acid metabolism and lipid droplet formation. Cells 8, 182 (2019). source
• Supported

  Citation 146 is attached to the astrocyte portion of the sentence. In Results, under “ApoE4 Impairs Astrocytic FA Degradation and Leads to LD Accumulation” (page unavailable), the paper reports substantially more lipid accumulation in lipid droplets in cultured ApoE4 astrocytes than in ApoE3 astrocytes. The separately cited neuron and microglia portions are outside this citation’s scope. (LLM, conf=0.94)

  cites [177] Qi, G. et al. ApoE4 impairs neuron–astrocyte coupling of fatty acid metabolism. Cell Rep. 34, 108572 (2021). source
• Supported

  Citation 178 is attached to the microglia part of the sentence, not the astrocyte or neuron parts. The Abstract reports APOE-dependent lipid droplet accumulation in human microglia after fibrillar Aβ exposure, and the “Lipid-associated ACSL1+ microglia in AD” section compares APOE4/4 with APOE3/3 microglia. Page numbers are unavailable in our copy. (LLM, conf=0.92)

  cites [178] Haney, M. S. et al. APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia. Nature 628, 154–161 (2024). source

In the paper

“in vitro studies have indicated that this mitochondrial dysfunction partly results from a blockade of mitophagy owing to APOE4-mediated lysosomal dysfunction, which leads to an accumulation of damaged and dysfunctional mitochondrial in APOE4 carriers167–169.”

What the sources say

• Partly supported

  The Results (page not provided) show that apoE4-expressing cells accumulated mitochondrial proteins, including a marker used for mitophagy, and failed to clear aggregates under starvation. The Discussion interprets this as implying lysosomal dysfunction. The paper does not demonstrate a blockade of mitophagy or show that damaged, dysfunctional mitochondria accumulate in APOE4 carriers; those conclusions go beyond the cell findings. (LLM, conf=0.87)

  cites [167] Parcon, P. A. et al. Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs. Alzheimers Dement. 14, 230–242 (2018). sourceExperimental — accuracy not yet measured
• Supported

  The APOE4 section reports that APOE4-expressing cells accumulate mitochondrial proteins and links this to blocked autophagy and mitophagy, likely through impaired expression of genes involved in lysosomal function. It also reports defective lysosomal degradation in APOE4-expressing astrocytes and describes the evidence for damaged-mitochondria accumulation as suggestive, consistent with the citing sentence’s attribution to in vitro studies. (LLM, conf=0.88)

  cites [168] Mary, A., Eysert, F., Checler, F. & Chami, M. Mitophagy in Alzheimer’s disease: molecular defects and therapeutic approaches. Mol. Psychiatry 28, 202–216 (2023). source
• Partly supported

  The Results and Discussion (pages unavailable) link ApoE4-related lysosomal dysfunction to impaired mitochondrial degradation and accumulation of dysfunctional mitochondria in cultured human astrocytes. The Discussion describes mitophagy impairment as a suggested mechanism and says the study did not directly establish altered mitochondrial turnover. The claim extends this finding to APOE4 carriers generally and presents a mitophagy blockade more definitively than the paper does. (LLM, conf=0.85)

  cites [169] Lee, H. et al. ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes. Cell Rep. 42, 113183 (2023). sourceExperimental — accuracy not yet measured

In the paper

“peripheral APOE seems to influence the brain partly by impacting the BBB.”

What the sources say

• Partly supported

  The paper’s Abstract reports that APOE affects BBB integrity in mice and that BBB breakdown permits blood-derived proteins to enter the brain. But the mechanism it examines involves astrocyte-secreted APOE; our copy does not establish that peripheral APOE has this effect. (LLM, conf=0.86)

  cites [183] Bell, R. D. et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512–516 (2012). sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion reports that ApoE4 produced by astrocytes impairs BBB integrity, supporting an effect of ApoE on the barrier. It does not establish that peripherally produced ApoE influences the brain through the BBB; the Introduction says the peripheral and brain pools rarely mix. (LLM, conf=0.85)

  cites [184] Jackson, R. J. et al. APOE4 derived from astrocytes leads to blood–brain barrier impairment. Brain 145, 3582–3593 (2022). sourceExperimental — accuracy not yet measured
• Partly supported

  The Introductory Paragraph reports BBB breakdown in APOE4 carriers and suggests that it contributes to cognitive decline. It does not distinguish peripheral APOE from APOE produced within the brain, so it does not establish that peripheral APOE acts through the BBB. (LLM, conf=0.86)

  cites [185] Montagne, A. et al. APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature 581, 71–76 (2020). sourceExperimental — accuracy not yet measured

In the paper

“when APOE4 was knocked out from astrocytes, the BBB was able to repair itself, indicating that APOE4 produced by astrocytes is responsible for this BBB leakage184.”

What the sources say

• Supported

  The Discussion reports that BBB leakage in humanized APOE4 mice was rescued after ApoE4 was knocked out from astrocytes. It concludes that astrocyte-produced ApoE4 negatively affects BBB integrity, supporting the citing sentence in the context of this mouse model. (LLM, conf=0.92)

  cites [184] Jackson, R. J. et al. APOE4 derived from astrocytes leads to blood–brain barrier impairment. Brain 145, 3582–3593 (2022). source

In the paper

“APOE4 is associated with increased oligomerization and deposition of Aβ in vitro and in vivo113,115,192”

What the sources say

• Partly supported

  The Discussion reports in vitro and in vivo evidence that apoE, particularly apoE4, promotes Aβ oligomerization. The Introduction also reports greater fibrillar Aβ deposition with apoE4 in brains and mice. It does not support increased deposition in vitro; the Results instead note that earlier in vitro assays found apoE inhibited Aβ fibrillization. (LLM, conf=0.86)

  cites [113] Hashimoto, T. et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J. Neurosci. 32, 15181–15192 (2012). sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion (page not available in our copy) reports greater Aβ deposition in the brains of people with apoE4 and in APP mouse models. The paper proposes that apoE4 stabilizes soluble Aβ oligomeric intermediates, but its in vitro results show delayed overall aggregation, not increased oligomerization and deposition in vitro. (LLM, conf=0.87)

  cites [115] Garai, K., Verghese, P. B., Baban, B., Holtzman, D. M. & Frieden, C. The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry 53, 6323–6331 (2014). sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [192] Koffie, R. M. et al. Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β. Brain 135, 2155–2168 (2012). source

In the paper

“Gene therapy has already been efficacious in other neurodegenerative diseases, most notably spinal muscular atrophy200,201.”

What the sources say

• Partly supported

  The Results report improved motor-milestone response and survival with nusinersen in infants with spinal muscular atrophy. But the paper describes nusinersen as an antisense oligonucleotide drug, not gene therapy, and its trial does not establish efficacy for gene therapy. Section labels are available in our copy, but page numbers are not. (LLM, conf=0.90)

  cites [200] Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017). sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [201] Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017). source

In the paper

“an APOE Christchurch-mimetic antibody that disrupts APOE–heparin binding has shown promise in reducing tau hyperphosphorylation in mouse models of tauopathy199.”

What the sources say

• Supported

  The Results section reports that the Christchurch-mimetic antibody 7C11.mAb strongly inhibited ApoE3 and ApoE4 binding to heparin. It also reports that the antibody reduced ApoE3-induced tau hyperphosphorylation in the retinas of P301S tauopathy-model mice. Page numbers are unavailable in our copy. (LLM, conf=0.93)

  cites [199] Marino, C. et al. APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Alzheimers Dement. 20, 819–836 (2023). source

In the paper

“Liver X receptors and retinoid X receptors are known to increase APOE lipidation207,208.”

What the sources say

• Partly supported

  The Results report that LXR and RXR ligands increased apoE mRNA expression in macrophages, and the paper identifies LXR/RXR heterodimers as regulators of apoE transcription. It does not report an increase in APOE lipidation—the loading of lipids onto the APOE protein—so the claim substitutes a different outcome for the one studied. (LLM, conf=0.87)

  cites [207] Laffitte, B. A. et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl Acad. Sci. USA 98, 507–512 (2001). sourceExperimental — accuracy not yet measured
• Supported

  The Introduction (page not provided) says the RXR–LXR system regulates expression of the apoE-lipidating proteins ABCA1 and ABCG1. The Discussion (page not provided) reports that the RXR agonist bexarotene increased both proteins and apoE lipidation in apoE3 and apoE4 mouse hippocampal samples, supporting the claim's mechanistic paraphrase. (LLM, conf=0.90)

  cites [208] Boehm-Cagan, A. & Michaelson, D. M. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. J. Neurosci. 34, 7293–7301 (2014). source

In the paper

“APOE continues to be the strongest contributor to AD heritability, despite the discovery of more than 80 risk loci in large GWAS over the past few years20.”

What the sources say

• Partly supported

  The Discussion reports 75 independent risk loci for Alzheimer’s disease and related dementias, not more than 80; the GRS section counts 83 genome-wide-significant variants, which are not 83 loci. The GRS section treats APOE separately and reports a substantial association with AD risk, but it does not establish that APOE is the strongest contributor to AD heritability. No page numbers are available in our copy. (LLM, conf=0.85)

  cites [20] Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022). sourceExperimental — accuracy not yet measured

In the paper

“The single amino acid changes in the different APOE isoforms result in slightly different structures, which have a strikingly large effect on the binding affinities of APOE to lipids, Aβ and receptors99,111,116,140.”

What the sources say

• Partly supported

  The Historical Progress section says single amino acid substitutions can dramatically change ApoE lipoprotein characteristics and binding properties, and the ApoE Receptors section reports dramatically reduced LDLR binding by ApoE2 (page numbers unavailable). However, the Conclusion says structural interactions *may* drive isoform-specific binding to receptors, lipids and Aβ. The ApoE–Aβ section describes findings that vary with lipidation state, so the claim overstates a uniformly large, established effect on all three binding affinities. (LLM, conf=0.86)

  cites [99] Chen, Y., Strickland, M. R., Soranno, A. & Holtzman, D. M. Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis. Neuron 109, 205–221 (2021). sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction (page unavailable) says the ApoE isoforms differ at two amino acid positions and describes structural differences and distinct lipid-particle associations. The Discussion and Results (pages unavailable) report isoform-specific interactions with Aβ. They do not establish a strikingly large effect on binding affinities across lipids, Aβ, and receptors; in particular, the paper reports no isoform-specific receptor-binding affinity result. (LLM, conf=0.87)

  cites [111] Jones, P. B. et al. Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain. PLoS One 6, e14586 (2011). sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion (p. 13252) reports that ApoE4 has a more closed conformation and is more lipidated than ApoE2 and ApoE3, and the paper finds isoform-dependent ApoE–Aβ association. It does not establish that single amino acid changes cause these differences, or show a strikingly large effect on binding affinities to lipids and receptors; its proposed structural explanation for Aβ binding is explicitly tentative. (LLM, conf=0.88)

  cites [116] Kara, E. et al. A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE)-amyloid beta complexes depends on ApoE isoform and cell type. J. Biol. Chem. 293, 13247–13256 (2018). sourceExperimental — accuracy not yet measured
• Partly supported

  The paper identifies the single amino acid differences among APOE isoforms and reports differences in their conformation and lipid profiles (Abstract; page not supplied). It does not establish a strikingly large effect on binding affinities: the paper says how those substitutions produce the observed changes requires further study, and whether conformation or lipidation affects interactions with amyloid β or receptors remains largely unknown. (LLM, conf=0.88)

  cites [140] Kara, E. et al. Isoform- and cell type-specific structure of apolipoprotein E lipoparticles as revealed by a novel Forster resonance energy transfer assay. J. Biol. Chem. 292, 14720–14729 (2017). sourceExperimental — accuracy not yet measured

In the paper

“Multiple small molecules have been designed to ‘correct’ the conformation of APOE4 so that it resembles that of APOE3 or APOE2 (refs. 213–217)”

What the sources say

• Supported

  The Discussion identifies two small-molecule structure correctors, GIND25 and PH002, and says they convert apoE4 into a molecule resembling apoE3 structurally and functionally. That supports the claim’s ‘APOE3 or APOE2’ phrasing through its APOE3 alternative; the passage does not establish resemblance to APOE2. Page numbers were not supplied in our copy. (LLM, conf=0.93)

  cites [213] Brodbeck, J. et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J. Biol. Chem. 286, 17217–17226 (2011). source
• Supported

  The Abstract states that small-molecule structure correctors convert apoE4 to an apoE3-like conformation and identifies additional correctors. It also explains that apoE2 and apoE3 share more open structures because both have Cys-112, supporting the comparison to either isoform. (LLM, conf=0.88)

  cites [214] Chen, H. K. et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J. Biol. Chem. 287, 5253–5266 (2012). source
• Supported

  The ‘Identification of Small-Molecule Structure Correctors and Their Mechanism of Action’ section (page not provided) reports multiple small molecules that disrupt apoE4 domain interaction. It specifically says two compounds converted apoE4 into an apoE3-like molecule, supporting the claim’s ‘apoE3 or apoE2’ comparison. (LLM, conf=0.90)

  cites [215] Mahley, R. W. & Huang, Y. Small-molecule structure correctors target abnormal protein structure and function: the structure corrector rescue of apolipoprotein E4-associated neuropathology. J. Med. Chem. 55, 8997–9008 (2012). source
• ?Not checked — no full text of the sourcecites [216] Petros, A. M. et al. Fragment-based discovery of an apolipoprotein E4 (apoE4) stabilizer. J. Med. Chem. 62, 4120–4130 (2019). source
• Partly supported

  The Results section says the authors identified multiple small-molecule structure correctors that make APOE4 structurally and functionally APOE3-like, and tested one of them, PH002. It does not say that the correctors make APOE4 resemble APOE2. (LLM, conf=0.86)

  cites [217] Wang, C. et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med. 24, 647–657 (2018). sourceExperimental — accuracy not yet measured

In the paper

“CASP7 rs10553596 and SERPINA3 rs4934-A/A have also been suggested to confer resilience against AD in people homozygous for APOEε4 aged >75 years27.”

What the sources say

• ?Not checked — no full text of the sourcecites [27] Huq, A. J. et al. Genetic resilience to Alzheimer’s disease in APOE ε4 homozygotes: a systematic review. Alzheimers Dement. 15, 1612–1623 (2019). source

In the paper

“Overall, these data indicate that the APOEε4 allele is functionally dominant over the APOEε2 allele.”

In the paper

“This observation suggests that APOE drives differential neurotoxic effects or neural network vulnerability that is independent of neuropathology severity.”

In the paper

“The rare APOEε2 homozygotes are at increased risk of developing hyperlipoproteinaemia type III (also known as familial dysbetalipoproteinaemia), characterized by very high triglyceride levels89.”

What the sources say

• ?Not checked — no full text of the sourcecites [89] Ghiselli, G., Gregg, R. E., Zech, L. A., Schaefer, E. J. & Brewer, H. B. Phenotype study of apolipoprotein E isoforms in hyperlipoproteinaemic patients. Lancet 2, 405–407 (1982). source

In the paper

“Lipids are loaded onto APOE via transmembrane ATP-binding cassette (ABC) transporters such as ABCA1 and ABCG1 (ref. 98) (Fig. 2a).”

What the sources say

• ?Not checked — no full text of the sourcecites [98] Hirsch-Reinshagen, V. et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279, 41197–41207 (2004). source

In the paper

“neurons produce APOE in times of stress, albeit to a lesser extent96.”

What the sources say

• ?Not checked — no full text of the sourcecites [96] Xu, Q. et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26, 4985–4994 (2006). source

In the paper

“These preclinical findings indicate that mimetic peptides designed to prevent APOE binding to either Aβ or APOE receptors could be therapeutically viable.”

In the paper

“indicating that directly targeting APOE lipidation is an effective therapeutic approach212”

What the sources say

• ?Not checked — no full text of the sourcecites [212] Boehm-Cagan, A. et al. ABCA1 agonist reverses the ApoE4-driven cognitive and brain pathologies. J. Alzheimers Dis. 54, 1219–1233 (2016). source